Novel Agent Curbs Alzheimer's-Related Agitation

More than half of participants in the open-label extension period of the randomized clinical trial responded to the medication, which was associated with a 3.6-fold lower risk for relapse compared with placebo.

In the open-label period, 178 adults with probable AD and clinically significant agitation received AXS-05 for up to 9 weeks. Rates of discontinuation in the double-blind period owing to adverse events were low . Three serious AEs were reported: one in the AXS-05 group , which was not related to study medication, and two in the placebo group (cardiac arrest,

"Agitation is a common, distressing, and sometimes safety issue for people fighting Alzheimer's disease, and there's very little evidence for efficacy and significant side effect issues for current medical management of agitation in Alzheimer's disease," said Finney, who was not part of the study.

Law Law Latest News, Law Law Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Neutral Result With Novel Agent in Diabetic CardiomyopathyThe ARISE-HF trial testing aldose reductase inhibition in asymptomatic diabetic cardiomyopathy did not meet its endpoint but hints at a mechanism that might prevent it.
Source: Medscape - 🏆 386. / 55 Read more »

Supreme Court to hear challenge to Biden's 'ghost guns' curbsThe U.S. Supreme Court on Monday agreed to decide the legality of a federal regulation aimed at reining in homemade 'ghost guns' as President Joe Biden's administration combats the increasing use of the largely untraceable weapons in crimes nationwide.
Source: KSLcom - 🏆 549. / 51 Read more »